Celcuity Inc. CELC
otherwise provided in this Annual Report, references to the "Company," "we," "us," and "our"
and similar references refer to Celcuity Inc., a Delaware corporation. We own various unregistered trademarks and service marks, including
our corporate logo. Solely for convenience, the trademarks, trade names and service marks in this Annual Report, including those owned
by third parties, may be referred to without the ®,TM or SM symbols, but such references should
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $145.0M | $104.2M | $60.6M | $35.3M | $25.8M | $7.7M | $6.3M | $6.3M | $5.0M | $3.1M |
| SG&A | $27.2M | $9.1M | $5.6M | $4.1M | $2.6M | $1.9M | $1.5M | $1.6M | $972.5K | $263.7K |
| Total operating expenses | $172.2M | $113.3M | $66.2M | $39.4M | $28.4M | $9.6M | $7.8M | $7.9M | $6.0M | $3.3M |
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M | -$28.4M | -$9.6M | -$7.8M | -$7.9M | -$6.0M | -$3.3M |
| Interest expense | $17.1M | $10.3M | $5.3M | $2.1M | $1.3M | $120 | $159 | $111 | $451.7K | $0 |
| Pre-tax income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M | -$9.5M | -$7.4M | -$7.5M | -$6.3M | -$3.3M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M | -$9.5M | -$7.4M | -$7.5M | -$6.3M | -$3.3M |
| EPS, basic | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | — | — | — | — | — |
| EPS, diluted | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | -0.92 | -0.72 | -0.74 | -0.84 | -0.52 |
| Shares, diluted (wtd. avg.) | $46.8M | $39.4M | $23.7M | $15.4M | $13.4M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.7M | $22.5M | $30.7M | $24.6M | $84.3M | $11.6M | $18.7M | $15.9M | $2.7M | $5.9M |
| Short-term investments | $275.8M | $212.6M | $149.9M | $144.0M | — | — | $0 | $9.0M | $21.6M | $0 |
| Total current assets | $465.7M | $244.6M | $190.6M | $175.2M | $85.4M | $12.2M | $19.3M | $25.2M | $24.5M | $5.9M |
| Property, plant and equipment | $499.0K | $336.0K | $228.8K | $260.3K | $312.4K | $558.9K | $833.5K | $813.6K | $280.1K | $144.9K |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M | $85.9M | $13.0M | $20.3M | $26.0M | $32.0M | $6.1M |
| Accounts payable | $6.4M | $9.4M | $5.1M | $2.6M | $1.5M | $217.4K | $142.8K | $119.8K | $71.9K | $331.5K |
| Total current liabilities | $44.2M | $31.7M | $14.2M | $6.9M | $2.5M | $1.2M | $911.3K | $662.3K | $578.1K | $445.4K |
| Long-term debt | $137.5M | $105.1M | $37.6M | $35.8M | $16.0M | — | — | — | — | — |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M | $17.2M | $1.3M | $983.2K | $682.2K | $578.1K | $445.4K |
| Retained earnings | -$448.9M | -$271.9M | -$160.1M | -$96.3M | -$55.9M | -$26.3M | -$16.8M | -$9.5M | -$2.0M | -$8.3M |
| Total equity | $100.6M | $115.6M | $139.8M | $133.8M | $68.7M | $11.7M | $19.3M | $25.3M | $31.4M | $5.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M | -$20.3M | -$7.1M | -$6.0M | -$6.1M | -$4.9M | -$2.9M |
| Depreciation and amortisation | $167.0K | $130.0K | $142.8K | $210.9K | $303.2K | $385.6K | $339.0K | $223.0K | $104.7K | $73.1K |
| Stock-based compensation | $21.4M | $7.0M | $4.9M | $4.6M | $2.6M | $1.8M | $1.0M | $1.2M | $874.4K | $187.3K |
| Capital expenditure | $249.0K | $250.0K | $97.6K | $158.8K | $81.9K | $89.4K | $380.2K | $629.6K | $239.8K | $40.9K |
| Investing cash flow | -$64.1M | -$63.1M | -$5.0M | -$144.0M | -$81.4K | -$89.4K | $8.5M | $19.1M | -$29.0M | -$40.9K |
| Financing cash flow | $360.6M | $138.4M | $64.9M | $120.3M | $93.0M | $138.0K | $259.3K | $236.7K | $30.7M | $3.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012801.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $47.31B | — | 35.9% |
| LH | LABCORP HOLDINGS INC. | $26.51B | 31.3x | 7.2% |
| DGX | QUEST DIAGNOSTICS INC | $26.17B | 27.1x | 11.8% |
| GH | Guardant Health, Inc. | $21.66B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $7.08B | — | 97.0% |
| RDNT | RadNet, Inc. | $5.80B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $4.61B | 709.9x | 100.0% |
| GRAL | GRAIL, Inc. | $3.59B | — | 17.2% |